Crinetics Pharmaceuticals (CRNX) Free Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$125.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 41.09% year-over-year to -$125.2 million; the TTM figure through Mar 2026 stood at -$420.1 million (down 55.76% YoY), while the FY2025 annual figure was -$383.7 million, down 63.94% from the prior year.
• Free Cash Flow was -$125.2 million for Q1 2026 at Crinetics Pharmaceuticals, down from -$98.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$13.6 million in Q1 2022 to a low of -$125.2 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$60.5 million across 5 years, with a median of -$49.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 32.15% in 2022, then plunged 198.86% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$36.8 million in 2022, then declined by 3.05% to -$37.9 million in 2023, then tumbled by 79.04% to -$67.9 million in 2024, then plunged by 45.22% to -$98.6 million in 2025, then declined by 26.94% to -$125.2 million in 2026.
• The last three Free Cash Flow figures came in at -$125.2 million (Q1 2026), -$98.6 million (Q4 2025), and -$106.3 million (Q3 2025), per Business Quant data.